Octapharma identifies Octagam problem
This article was originally published in Scrip
Executive Summary
Octapharma AG says it has identified the problem that forced it to withdraw voluntarily its Octagam (human normal immunoglobulin) from various markets in response to an increase in reported thromboembolic events (TEEs). The firm said it believes that corrective measures can be implemented without delay, with resolution possible by the end of 2010.